Related Experiment Video
Updated: May 29, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Age-related penetrance of hereditary atypical hemolytic uremic syndrome
Maren Sullivan1, Lisa A Rybicki, Aurelia Winter
1Department of Nephrology, Section of Preventive Medicine, University Medical Center, Albert-Ludwigs-University, Freiburg, Germany.
Insights
Hereditary atypical hemolytic uremic syndrome (aHUS) shows reduced penetrance in relatives compared to index patients. This finding is crucial for understanding aHUS and for genetic counseling in families with these mutations.
Area of Science:
- Genetics
- Nephrology
- Pediatrics
Background:
- Hereditary atypical hemolytic uremic syndrome (aHUS) is a severe kidney disease linked to mutations in complement genes like CFH, CD46, and CFI.
- Genetic testing of relatives is key for prevention, but clinical data for family counseling are limited.
Purpose of the Study:
- To determine the age-adjusted penetrance of aHUS in relatives of affected individuals.
- To provide data for improved genetic counseling regarding hereditary aHUS.
Main Methods:
- Direct sequencing was used to screen for familial mutations in 61 relatives of 33 aHUS index patients from a German registry.
- Demographic and clinical data were collected, and age-adjusted penetrance was calculated for CFH, CD46, and CFI mutations.
Main Results:
- Mutations were detected in 31 of 61 relatives. Overall penetrance at age 40 was significantly lower in mutation-positive relatives (10%) compared to index patients (67%).
- Specific penetrance reductions were observed for CFH (6% vs. 67%) and CD46 (21% vs. 70%) mutation carriers.
Conclusions:
- Age-adjusted penetrance of hereditary aHUS is substantially lower in mutation-carrying relatives than in probands.
- These findings are vital for understanding aHUS disease progression and for providing accurate genetic counseling to at-risk families.
Abstract:
Hereditary atypical hemolytic uremic syndrome (aHUS), a dramatic disease frequently leading to dialysis, is associated with germline mutations of the CFH, CD46, or CFI genes. After identification of the mutation in an affected aHUS patient, single-site gene testing of relatives is the preventive care perspective. However, clinical data for family counselling are scarce. From the German-Speaking-Countries-aHUS-Registry, 33 index patients with mutations were approached for permission to offer relatives screening for their family-specific mutations and to obtain demographic and clinical data. Mutation screening was performed using direct sequencing. Age-adjusted penetrance of aHUS was calculated for each gene in index cases and in mutation-positive relatives. Sixty-one relatives comprising 41 parents and 20 other relatives were enrolled and mutations detected in 31/61. In total, 40 research participants had germline mutations in CFH, 19 in CD46 and in 6 CFI. Penetrance at age 40 was markedly reduced in mutation-positive relatives compared to index patients overall with 10% versus 67% (P < 0.001); 6% vs. 67% (P < 0.001) in CFH mutation carriers and 21% vs. 70% (P= 0.003) in CD46 mutation carriers. Age-adjusted penetrance for hereditary aHUS is important to understand the disease, and if replicated in the future, for genetic counselling.
Related Concept Videos
Huntington Disease l: Introduction
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic Lingo
Pedigree Analysis
Probability Laws
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

